DDrare: Database of Drug Development for Rare Diseases

195. ヌーナン症候群
［臨床試験数：14，薬物数：15（DrugBank：5），標的遺伝子数：2，標的パスウェイ数：9］

Searched query = "Noonan syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Glucose; Growth hormone; LOVASTATIN; Lamotrigin; Lamotrigin beta; Lovastatin; MAXOMAT ®, biosynthetic growth hormone; MEK162; Norditropin 24 IU; Norditropin SimpleXx; Other: Oral Glucose tolerance test; RhIGF-1/rhIGFBP-3; RhIGFBP-3; Simvastatin; Somatropin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00452725 (ClinicalTrials.gov)	October 1997	23/3/2007	Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome	Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome	Noonan Syndrome	Drug: MAXOMAT ®, biosynthetic growth hormone	Sanofi	NULL	Completed	3 Years	15 Years	Both	36	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00452725
(ClinicalTrials.gov)

October 1997

23/3/2007

Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome

Effect of the Growth Hormone MAXOMAT ® on the Growth of Small Children and Adolescents (<-2 SD) Due to NOONAN's Syndrome

Noonan Syndrome

Drug: MAXOMAT ®, biosynthetic growth hormone

Sanofi

NULL

Completed

3 Years

15 Years

Both

Phase 3

France